Alphatec Holdings Partners with Theradaptive to Transform Spinal Regenerative Medicine

Alphatec Holdings Partners with Theradaptive to Advance Spinal Regenerative Medicine

Alphatec Holdings, Inc. (Nasdaq: ATEC), a prominent player in spine surgery innovation, has forged a strategic partnership with Theradaptive, Inc., a clinical-stage regenerative medicine company. This collaboration grants ATEC exclusive rights to market Theradaptive's OsteoAdapt® osteoinductive bone graft in the U.S., representing a significant milestone in the field of regenerative medicine within spine surgery. The agreement encompasses a combination of upfront payments, milestone payments, and a perpetual royalty structure, designed to create substantial long-term value for both companies involved.

OsteoAdapt utilizes Theradaptive's proprietary AMP2™ protein technology, which is currently undergoing clinical trials for spinal and dental applications. The technology has already received three FDA Breakthrough Device Designations, underscoring its potential to address critical medical needs in bone regeneration. Alphatec's CEO, Pat Miles, highlights that this partnership is pivotal in enhancing the company’s procedural ecosystem and aims to redefine clinical outcomes for spinal fusion procedures. By integrating such advanced regenerative solutions, ATEC aims to improve the standard of care in spinal surgeries.

The partnership also aligns with Theradaptive's ongoing initiatives to expedite the commercialization of its innovative technology. To support this venture, Theradaptive has launched a Series B investment round, which will fund the OASIS Pivotal trial and scale up its manufacturing operations. Luis Alvarez, Ph.D., Founder and CEO of Theradaptive, expresses strong confidence in ATEC’s role as the ideal partner to deliver their groundbreaking technology to patients. This strategic alignment is expected to significantly enhance patient outcomes in spinal fusion treatments, driving innovation and advancements in regenerative medicine.

In addition to the partnership, the collaboration between ATEC and Theradaptive signals a broader trend towards incorporating biologic solutions in surgical practices, which can lead to improved recovery times and success rates for patients. As the spine industry continues to evolve, such alliances are critical in fostering an environment where innovative therapies can thrive and ultimately benefit patient care.

Overall, the partnership between Alphatec Holdings and Theradaptive marks a pivotal development in regenerative medicine for spinal therapies, setting the stage for future advancements that have the potential to reshape the landscape of spinal surgery.